Mineralys Therapeutics, Inc. (MLYS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$17.00+6.32%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · MLYS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||
| R&D Expenses | 292.8 | 132.0 | 168.6 | 70.4 | 26.3 | — |
| Operating Income | (389.7) | (170.6) | (192.4) | (84.7) | (31.5) | — |
| Earnings from Continuing Operations | ||||||
| Other Non-Operating Income / Expenses | 19.8 | 16.0 | 14.6 | 12.8 | 1.7 | — |
| Net Income | ||||||
| Net Income | (370.0) | (154.7) | (177.8) | (71.9) | (29.8) | — |
| Per Share | ||||||
| Basic EPS | (4.16) | (2.29) | (3.66) | (1.99) | (5.77) | — |
| Diluted EPS | (4.16) | (2.29) | (3.66) | (1.99) | (5.77) | — |
| Basic Weighted Avg Shares | 89.0 | 67.7 | 48.5 | 36.2 | 5.2 | — |
| Diluted Weighted Avg Shares | 89.0 | 67.7 | 48.5 | 36.2 | 5.2 | — |
| Supplemental | ||||||
| EBITDA | — | (170.5) | (192.4) | (84.7) | — | — |
| EBIT | (389.7) | (170.6) | (192.4) | (84.7) | (31.5) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.